Agenus Reports 51% 18-Month Survival With BOT+BAL in MSS Colorectal Cancer

Coverage, in order

1. 4d ago
   
   OncoDaily obscure

   Agenus Reports 51% 18-Month Survival With BOT+BAL in MSS Colorectal Cancer

   For years, microsatellite-stable (MSS) colorectal cancer has remained one of immunotherapy’s most difficult challenges. While immune checkpoint inhibitors have transformed treatment for patients with mismatch repair-deficient tumors, most patients with

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.